Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The deal comes two months after BD completed the spinoff of its diabetes business as a separate, publicly traded company.
Becton Dickinson is known worldwide for its diabetes products. Now the medical technologies giant plans to spin off its diabetes care business as a separate, publicly traded company, leaving BD to focus on its other core segments.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
One reason for the deal is Bard will help expand BD’s focus on the treatment of disease states beyond diabetes.
Given Vyaire's annual earnings and the market potential in respiratory diseases and anesthesia, the $500 million price tag seems like a good deal for Apax.